Treatments:Diabetes
From Proteopedia
(Difference between revisions)
												
			
			|  (→Glucagon-like peptide-1 (GLP-1) agonist) | |||
| Line 15: | Line 15: | ||
| =====[[Glucagon-like peptide 1 receptor|Glucagon-like peptide-1]] (GLP-1) agonist===== | =====[[Glucagon-like peptide 1 receptor|Glucagon-like peptide-1]] (GLP-1) agonist===== | ||
| * [[Victoza]] - Generic: [[Liraglutide]] | * [[Victoza]] - Generic: [[Liraglutide]] | ||
| + | * [[Ozempic]] - Generic: [[Semaglutide]] | ||
| + | |||
| =====Mechanism is not completely understood===== | =====Mechanism is not completely understood===== | ||
| *[[Metformin]] - Generic: [[N,N-dimethylbiguanide]] | *[[Metformin]] - Generic: [[N,N-dimethylbiguanide]] | ||
Revision as of 21:23, 20 December 2024
| 
 Insulin
 Dipeptidyl peptidase IV Inhibitor
 Peroxisome Proliferator-Activated Receptor Agonist
 Glucagon-like peptide-1 (GLP-1) agonist
 Mechanism is not completely understood
 Inhibitors of the sodium glucose co-transporter-2 (SGLT-2) | 
Proteopedia Page Contributors and Editors (what is this?)
Alexander Berchansky, David Canner, Michal Harel, Karsten Theis
